Morroniside _MMP 抑制剂 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEMorronisideCat. No.: HY-N0532CAS No.: 25406-64-8分式: CHO分量: 406.38作靶点: MMP; Apoptosis作通路: Metabolic Enzyme/Protease; Apoptosis储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 125 mg/mL (307.5

2、9 mM; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 2.4608 mL 12.3038 mL 24.6075 mL5 mM 0.4922 mL 2.4608 mL 4.9215 mL10 mM 0.2461 mL 1.2304 mL 2.4608 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。体内实验 请根据您的实验动物和给药式选择适当的溶解案，配制前请先配制澄清的储备液，再依次添加助溶剂(为保证实验结果的可靠性，体内实验的作液，建议您现现配，当天使；澄清

3、的储备液可以根据储存条件，适当保存；以下溶剂前的百分 指该溶剂在您配制终溶液中的体积占)：1. 请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.08 mg/mL (5.12 mM); Clear solution2. 请依序添加每种溶剂： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.08 mg/mL (5.12 mM); Clear solution3. 请依序添加每种溶剂： 10% DMSO 90% corn oilSolubility: 2.08 mg

4、/mL (5.12 mM); Clear solution1/2 Master of Small Molecules 您边的抑制剂师www.MedChemEBIOLOGICAL ACTIVITY物活性 Morroniside 通过抑制神经元凋亡和 MMP9/2 的表达从发挥神经保护作。IC50 & Target MMP2 MMP9体内研究 Morroniside reduces the expression of MMP2 and MMP9 in an I/R injury model. Treatment with Morronisidesignificantly reduces I/Ras

5、sociated neuron apoptosis in a dose dependent m anner. The results dem onstrate that activecaspase3 and Bax are significantly upregulated in the m odel group com pared with the control group, while Bcl2 issignificantly downregulated. The expression of active caspase3 and Bax is significantly downreg

6、ulated by Morronisidetreatm ent in a dosedependent m anner, while the expression of Bcl2 is significantly upregulated 1. Morroniside hasan am eliorative effect on diabetes-induced alterations such as oxidative stress, inflam m ation, and apoptosis in the liverof type 2 diabetic db/db m ice 2.PROTOCO

7、LAnimal Rats 1Administration 1 A total of 50 adult male Sprague Dawley rats (age, 7 8 weeks; weight, 260 280 g) are used. Rats arerandomly assigned into five groups (n=10 in each). Rats in the control group undergo sham surgery. All otherrats undergo suture occluded surgery, with a 0.26 mm nylon mon

8、ofilament inserted through the rightcommon carotid artery and are divided into groups as follows: The cerebral I/R injury model group (model),no treatment; low dose group, 30 mg/kg/day Morroniside by gavage; moderate dose group, 90 mg/kg/dayMorroniside by gavage; high dose group, 270 mg/kg/day Morro

9、niside by gavage. Rats in the control andmodel groups receive an equal volume of normal saline 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Zeng G, et al. Morroniside protects against cerebral ischemia/reperfusion injury by inhibiting

10、neuron apoptosis and MMP2/9 expression.Exp Ther Med. 2018 Sep;16(3):2229-2234.2. Park CH, et al. Evaluation of morroniside, iridoid glycoside from Corni Fructus, on diabetes-induced alterations such as oxidative stress,inflammation, and apoptosis in the liver of type 2 diabetic db/db mice. Biol Pharm Bull. 2011;34(10):1559-65.McePdfHeightCaution: Product has not been fully va